Literature DB >> 19667979

The effects of apomorphine on visual perception in patients with Parkinson disease and visual hallucinations: a pilot study.

Linda Geerligs1, Anne Marthe Meppelink, Wiebo H Brouwer, Teus van Laar.   

Abstract

Visual hallucinations (VHs) often occur in patients with advanced Parkinson disease (PD). Overstimulation of dopamine receptors has been considered as one of the causes for VHs in PD. However, several clinical studies suggested that apomorphine infusion did not worsen existing VHs in PD, but could even improve VHs in some PD patients. This pilot study included 4 PD patients with VHs, who were examined before, during, and after an intravenous infusion with apomorphine. The examinations included tests for lower- and higher-order visual functions, attention, and motor functions. Apomorphine had a significantly positive effect on contrast sensitivity and showed a significantly negative effect on attention. These results may explain why apomorphine is able to improve VHs in PD in some patients with mainly visual perceptive problems, but may also worsen VHs in other patients because of impaired attention.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19667979     DOI: 10.1097/WNF.0b013e3181a6a92b

Source DB:  PubMed          Journal:  Clin Neuropharmacol        ISSN: 0362-5664            Impact factor:   1.592


  3 in total

Review 1.  Pharmacological Insights into the Use of Apomorphine in Parkinson's Disease: Clinical Relevance.

Authors:  Manon Auffret; Sophie Drapier; Marc Vérin
Journal:  Clin Drug Investig       Date:  2018-04       Impact factor: 2.859

Review 2.  The psychosis spectrum in Parkinson disease.

Authors:  Dominic H Ffytche; Byron Creese; Marios Politis; K Ray Chaudhuri; Daniel Weintraub; Clive Ballard; Dag Aarsland
Journal:  Nat Rev Neurol       Date:  2017-01-20       Impact factor: 42.937

Review 3.  The Many Faces of Apomorphine: Lessons from the Past and Challenges for the Future.

Authors:  Manon Auffret; Sophie Drapier; Marc Vérin
Journal:  Drugs R D       Date:  2018-06
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.